Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT05067127
Previous Study | Return to List | Next Study

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05067127
Recruitment Status : Recruiting
First Posted : October 5, 2021
Last Update Posted : August 8, 2022
Sponsor:
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

Brief Summary:
This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

Condition or disease Intervention/treatment Phase
C3G IC-MPGN C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G) Complement 3 Glomerulonephritis Dense Deposit Disease DDD Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN) Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Drug: Pegcetacoplan Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Actual Study Start Date : November 12, 2021
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : August 2024


Arm Intervention/treatment
Experimental: Group 1: Pegcetacoplan administration
Subcutaneous infusion of 20mL (1080 mg), twice weekly (for adults or adolescents >50kg), and the three other weight-based doses either of 10mL (540mg), 12mL (648mg), or 15mL (810mg)
Drug: Pegcetacoplan
Complement (C3) Inhibitor

Placebo Comparator: Group 2: Placebo administration
Subcutaneous infusion of either 10mL, 12mL, 15mL, or 20mL, twice weekly
Other: Placebo
Sterile solution of equal volume to active arm




Primary Outcome Measures :
  1. The proportion of subjects with a reduction from baseline in urine protein-to-creatinine ratio (uPCR) of at least 50% at Week 26 [ Time Frame: Baseline to week 26 ]

Secondary Outcome Measures :
  1. The proportion of subjects with eGFR values that are stable or improved [ Time Frame: Baseline to week 26 ]
  2. For subjects with evaluable renal biopsies, the change in the C3G histologic index activity score (adults only) [ Time Frame: Baseline to week 26 ]
  3. The proportion of subjects with evaluable renal biopsies showing decreases in C3c staining on renal biopsy (adults only) [ Time Frame: Baseline to week 26 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged at least 18 years; where approved, adolescents (aged 12-17 years) weighing at least 30 kg may also be enrolled.
  • A diagnosis of primary C3G or IC-MPGN (with or without previous renal transplant).
  • Evidence of active renal disease, based on one or more of the following:

    1. In adults or adolescents with a baseline renal biopsy, at least 2+ staining for C3c on the baseline renal biopsy collected during screening, per the central pathology laboratory.
    2. In adolescents not providing a baseline renal biopsy, at least one of the following:
  • Serum C5b-9 level above the upper limit of normal (ULN) during screening.
  • Serum C3 below the LLN during screening.
  • Presence of an active urine sediment during screening, as evidenced by hematuria with at least 5 red blood cells (RBCs) per high-power field (HPF) and/or red blood cell casts on local or central microscopic analysis of urine.
  • Presence of C3 nephritic factor within 6 months of screening, based on central lab results or medical history.
  • No more than 50% global glomerulosclerosis or interstitial fibrosis on the baseline biopsy, for adult subjects or adolescent subjects providing a baseline biopsy.
  • At least 1 g/day of proteinuria on a screening 24-hour urine collection, and a uPCR of at least 1000 mg/g on at least 2 first-morning urine samples collected during screening.
  • eGFR ≥30 mL/min/1.73 m2 calculated by the Chronic Kidney Disease-Epidemiology Collaboration creatinine equation for adults, or the Bedside Schwartz equation for adolescents.
  • Stable regimen for C3G/IC-MPGN treatment, as described below:

    1. Stable and optimized angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) therapy for at least 12 weeks prior to randomization, in the opinion of the investigator.
    2. Stable doses of other medications that can affect proteinuria (eg, steroids, mycophenolate mofetil (MMF) and/or other allowed immunosuppressants that the patient is receiving for treatment of C3G) for at least 8 weeks prior to the baseline renal biopsy, and at least 12 weeks prior to randomization.
  • Have received vaccinations against S pneumoniae, N meningitidis (types A, C, W, Y, and B), and H influenzae (type B) within 5 years prior to randomization or agree to receive vaccinations during screening.

Exclusion Criteria:

  • Previous exposure to pegcetacoplan.
  • C3G/IC-MPGN secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, a systemic autoimmune disease such as systemic lupus erythematosus, chronic antibody-mediated rejection, or a medication), in the opinion of the investigator.
  • Current or prior diagnosis of human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection or positive serology during screening that is indicative of infection with any of these viruses.
  • Weight more than 100 kg at screening.
  • Hypersensitivity to pegcetacoplan or to any of the excipients.
  • History of meningococcal disease.
  • Malignancy, except for the following:

    1. Cured basal or squamous cell skin cancer
    2. Curatively treated in situ disease
    3. Malignancy-free and off treatment for ≥5 years
  • An absolute neutrophil count <1000 cells/mm3 at screening.
  • Use of rituximab, belimumab, or any approved or investigational anticomplement therapy other than pegcetacoplan within 5 half-lives of that product prior to the screening period.
  • Female subjects who are pregnant or who are currently breastfeeding and are unwilling to discontinue for the duration of the study and for at least 90 days after the final dose of study drug.
  • Presence or suspicion of severe recurrent or chronic infections that, in the opinion of the investigator, may place the subject at unacceptable risk by study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05067127


Contacts
Layout table for location contacts
Contact: Apellis Clinical Trial Information Line 617-977-5700 clinicaltrials@apellis.com

Locations
Show Show 28 study locations
Sponsors and Collaborators
Apellis Pharmaceuticals, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Apellis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT05067127    
Other Study ID Numbers: APL2-C3G-310
First Posted: October 5, 2021    Key Record Dates
Last Update Posted: August 8, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glomerulonephritis
Glomerulonephritis, Membranoproliferative
Nephritis
Kidney Diseases
Urologic Diseases
Immune System Diseases